Pemigatinib, also known as INCB054828, is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. FGFR inhibitor INCB054828 binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells.
FGFR Inhibitors Related Products:
Infigratinib; PD173074; AZD4547; Danusertib; Brivanib alaninate; Lenvatinib; Lenvatinib mesylate; Nintedanib esylate; BLU9931; SKLB610; Roblitinib